LMR Partners’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
Other funds holding SYRE
LMR Partners's SYRE Position: Q3 2026 in Review
LMR Partners opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 47,000 shares worth $4.18M. The stake represents 0.01% of the portfolio and ranks #738 among its holdings. This is a return to the name: LMR Partners previously reported a position in SYRE as recently as Q1 2024.
LMR Partners first reported a position in SYRE in Q2 2022 and has held it in 4 quarters since. 286 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.
- LMR Partners held 47,000 shares of Spyre Therapeutics worth $4.18M as of Q3 2026.
- Spyre Therapeutics was a new LMR Partners position in Q3 2026.
- Spyre Therapeutics made up 0.01% of LMR Partners's portfolio in Q3 2026, its #738 holding.
- LMR Partners first reported a position in Spyre Therapeutics in Q2 2022 and has held it in 4 quarters since.
- 286 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.
Based on LMR Partners's 13F filing for Q3 2026, filed 16 Nov 2026.